Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study-Reference-Cited by-同舟云学术

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

Published:2020-05 Issue:5 Volume:5 Page:441-453
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Lampertico Pietro,Buti Maria,Fung Scott,Ahn Sang Hoon,Chuang Wan-Long,Tak Won Young,Ramji Alnoor,Chen Chi-Yi,Tam Edward,Bae Ho,Ma Xiaoli,Flaherty John F,Gaggar Anuj,Lau Audrey,Liu Yang,Wu George,Suri Vithika,Tan Susanna K,Subramanian G Mani,Trinh Huy,Yoon Seung-Kew,Agarwal Kosh,Lim Young-Suk,Chan Henry L Y

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference31 articles.

1. Advancing age and comorbidity in a US insured population-based cohort of patients with chronic hepatitis B;Nguyen;Hepatology,2019

2. Progress toward hepatitis B control and elimination of mother-to-child transmission of hepatitis B virus—Western Pacific Region, 2005-2017;Woodring;MMWR Morb Mortal Wkly Rep,2019

3. Epidemiology of hepatitis B and the role of vaccination;Chang;Best Pract Res Clin Gastroenterol,2017

4. An aging population of chronic hepatitis B with increasing co-morbidities—a territory-wide study from 2000 to 2017;Wong;Hepatology,2019

5. 13-year nationwide cohort study of chronic kidney disease risk among treatment-naïve patients with chronic hepatitis B in Taiwan;Chen;BMC Nephrol,2015

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative evaluation of adverse drug reactions for tenofovir alafenamide and tenofovir disoproxil fumarate using the FAERS Database: a disproportionality analysis;Expert Opinion on Drug Safety;2024-08-19

2. Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study;The Lancet Gastroenterology & Hepatology;2024-08

3. Broadening clinical indications of tenofovir alafenamide in chronic hepatitis B;The Lancet Gastroenterology & Hepatology;2024-08

4. Current trends and advances in antiviral therapy for chronic hepatitis B;Chinese Medical Journal;2024-06-28

5. Entecavir vs. tenofovir disoproxil fumarate in the treatment of chronic hepatitis B patients with severe acute exacerbation;European Journal of Gastroenterology & Hepatology;2024-06-26